Rio Gutierrez Ocampo, FNP

Rio Ocampo practices at Ech: Mri Pro Plaza - Mri - HOPD in Loma Linda, California.

Rio Ocampo's NPI, 1679943054, was assigned on September 29, 2015. Rio Ocampo holds California license 95002595.

Rio Ocampo's primary practice is Ech: Mri Pro Plaza - Mri - HOPD, at 25455 Barton Rd, Loma Linda, CA 92354.

Rio Ocampo's primary practice is Ech: Mri Pro Plaza - Mri - HOPD in Loma Linda, California. Rio Ocampo is also affiliated with Loma Linda University Medical Center. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Rio Ocampo to 1 more group practice or clinic, named with a free account. Rio Ocampo's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Rio Ocampo practices, 3 sites in all. Vendor and product names are available with a free account.

Family is Rio Ocampo's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Rio Ocampo is licensed in California.

Dmand AI lists acute gastroduodenitis, bladder disease, chronic diabetes, diabetic emergency, eyelid inflammation, fibromyalgia and chronic pain, fluid and electrolyte imbalances and lower back pain among the conditions Rio Ocampo treats.

CMS data shows 91 Medicare services from Rio Ocampo across 1 procedure code in 2024, all of them office visits, for 80 Medicare patients. Medicare paid $5,959 for them. Every service was in an office.

CMS counts 80 Medicare patients who saw Rio Ocampo in 2024. The largest group is 65 to 74, with 35 patients. 73% of them have high blood pressure, and 58% have high cholesterol. 38% are also on Medicaid. Their average risk score is 1.18, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Rio Ocampo's median patient age at 55, with 69% women.

In 2024, Rio Ocampo wrote 4,388 Medicare Part D claims for 1,272 patients. 91% of them were for generic drugs. CMS names the drug for 3,787 of them, across 90 drugs with 11 or more claims each, at $217,288 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Rio Ocampo for performance year 2024, reported as part of a group. Rio Ocampo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Rio Ocampo as offering telehealth.

CMS Open Payments shows 4 general payments to Rio Ocampo from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $48.